{"entity":{"id":"nct07751991","kind":"trial","name":"A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML","aka":[],"tldr":"A phase 1 trial of CHM-029 run by Charm Therapeutics, now recruiting.","summary":"A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML is a phase 1 interventional study registered as NCT07751991 by Charm Therapeutics, with 40 participants planned, started 2026-09-28. Conditions recorded: AML (Acute Myeloid Leukemia). Interventions recorded: CHM-029.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07751991","url":"https://clinicaltrials.gov/study/NCT07751991"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["chm-029"],"companies":["charm-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07751991","phase":"1","setting":"A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029 as Monotherapy in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) With NPM1 Mutations, KMT2A or NUP98 Rearrangements","sponsor":"Charm Therapeutics","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07751991/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"chm-029","kind":"drug","name":"CHM-029","route":"/drugs/chm-029/"}],"company":[{"id":"charm-therapeutics","kind":"company","name":"CHARM Therapeutics","route":"/companies/charm-therapeutics/"}]}}